Filing Flows › Regenerative Medical Technology Group (RMTG) › Q3 2025
Regenerative Medical Technology Group (RMTG) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 19, 2025
Regenerative Medical Technology Group (RMTG) reported revenue of $1.2M for the third quarter 2025 (Q3 2025), +20% from a year earlier and +20% from the quarter before. Operating margin was -37.8%, net loss $4.4M (368.8% of revenue).
Regenerative Medical Technology Group, Q3 2025: revenue $1.2M (+20% year over year), operating margin -37.8%, net loss $4.4M, operating cash flow −$204K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | +20% | +20% |
| Operating profit | −$446K | — | — |
| Net earnings | −$4.4M | — | — |
| Operating cash flow | −$204K | — | — |
What changed
Revenue was $1.2M in Q3 2025, up 20% year over year and up 20% from the previous quarter.
Gross margin was 42.5%, down 33.3 points from a year earlier. Operating costs exceeded revenue by $446K, an operating margin of -37.8%. Operating expenses grew 30% against revenue growth of 20%. The fastest-growing cost line was Sales & marketing (+143%). The quarter ended with a net loss of $4.4M, wider than the previous quarter's $1.3M loss. Net interest and other expense of $3.9M was the main reason.
Operating cash flow was −$204K. Non-cash charges added back $76K of depreciation and amortization. Working capital and other items added $4.1M. Capital expenditures of $225K exceeded it, leaving free cash flow of −$429K.
Questions
What was Regenerative Medical Technology Group's revenue in the third quarter 2025?
Regenerative Medical Technology Group (RMTG) reported revenue of $1.2M for the third quarter 2025 (Q3 2025), +20% from a year earlier and +20% from the quarter before.
Was Regenerative Medical Technology Group profitable in the third quarter 2025?
Operating loss was $446K (-37.8% of revenue) and net loss $4.4M.
Source: Regenerative Medical Technology Group 10-Q on SEC EDGAR.